<?xml version="1.0" encoding="UTF-8"?>
<results title="testTrace">
 <result pre="Article Cyclophilin A and CD147: novel therapeutic targets for the" exact="treatment" post="of COVID-19 LiuChenglongavon BrunnAlbrechtbZhuDizhudi@fudan.edu.cnacâ�Ž[a], [b], [c], â�ŽCorresponding author at:"/>
 <result pre="was found to play a functional role in facilitating the" exact="infection" post="of host cells by SARS-CoV. The CyPA/CD147 interaction may"/>
 <result pre="prospects of cyclophilin A as a therapeutic target for the" exact="treatment" post="of coronavirus infection, especially coronavirus disease 2019 (COVID-19), and"/>
 <result pre="respiratory epidemics worldwide [19,20]. At present, there is no specific" exact="treatment" post="for coronavirus, and there is no effective treatment plan"/>
 <result pre="no specific treatment for coronavirus, and there is no effective" exact="treatment" post="plan for severely ill patients. Repurposing of individual drugs,"/>
 <result pre="intensity of COVID-19. However, such drugs are far from preventing" exact="infection" post="or disease. In deciding how to treat coronavirus infection,"/>
 <result pre="liver cancer metastasis, making it a potential target for the" exact="treatment" post="of liver disease [8]. 2.2 Cyclosporine A and cyclophilins"/>
 <result pre="CsA was originally discovered by Sanders in the process of" exact="screening" post="non-cytotoxic immunosuppressants, and it was developed for use in"/>
 <result pre="[4,35,36]. In 2011, it was reported that CsA inhibits CoV" exact="infection" post="[32]. In the same year, the Brunn team demonstrated"/>
 <result pre="(0.5â€&quot;3â€¯Î¼M), indicating that the CoV is less sensitive to CsA" exact="treatment" post="[32]. As an effective and panCoV inhibitor, CsA and"/>
 <result pre="have good research and development prospects. 2.4 CD147 in coronavirus" exact="infection" post="An extracellular matrix metalloproteinase inducer (CD147/EMMPRIN) is a transmembrane"/>
 <result pre="CD147 is involved in tumor development, plasmodium invasion and virus" exact="infection" post="[[12], [13], [14]]. CD147 can interact with cyclophilins as"/>
 <result pre="extracellular CyPA [15,16]. CD147 plays a critical role in the" exact="infection" post="of various viruses in the human body, such as"/>
 <result pre="cell. The CD147 molecule of the host cell can promote" exact="infection" post="of the host cell by the HIV-1 virus through"/>
 <result pre="HIV-1 virus through interaction with the virus-associated CyPA. During SARS-CoV" exact="infection" post="of host cells, the CD147 molecule works via a"/>
 <result pre="and that CD147 has a critical role in promoting the" exact="infection" post="of host cells by the virus. Surface plasmon resonance"/>
 <result pre="N protein of SARS-CoV, CD147 plays a role in facilitating" exact="infection" post="of host cells by SARS-CoV [18,19]. There are currently"/>
 <result pre="shows that CD147 can be a novel route for the" exact="infection" post="of SARS-CoV-2 as well as a novel target for"/>
 <result pre="of SARS-CoV-2 as well as a novel target for COVID-19" exact="treatment" post="[21]. CyPA may play a pivotal role in with"/>
 <result pre="CD147 in SARS-CoV-2 infection, and CyPA inhibitors may inhibit the" exact="infection" post="of SARS-CoV-2 by blocking the infection route. CyPA/CD147 interaction"/>
 <result pre="inhibitors may inhibit the infection of SARS-CoV-2 by blocking the" exact="infection" post="route. CyPA/CD147 interaction is also related to other diseases."/>
 <result pre="the replication of SARS-CoV intracellularly, but also may inhibit the" exact="infection" post="of SARS-CoV into host cells via interacting with CD147."/>
 <result pre="chronic hepatitis C Alisporivir block SARS-CoV and MERS-CoV replication. Combination" exact="treatment" post="with alisporivir and ribavirin increases the anti-MERS-CoV activity in"/>
 <result pre="Phase III completed NIM811 Image 3 Novartis Hepatitis C; HIV-1" exact="infection" post="Induces a dose-dependent reduction of HCV RNA in the"/>
 <result pre="indicating that they could be a candidate drug for the" exact="treatment" post="of CoV infection in humans [4,36]. CsA and its"/>
 <result pre="could be a candidate drug for the treatment of CoV" exact="infection" post="in humans [4,36]. CsA and its derivatives interrupt the"/>
 <result pre="the replication of MERS and SARS CoVs, and in cell-based" exact="infection" post="models, ribavirin further enhances alisporivir's antiviral effect [39]. 3"/>
 <result pre="and bioinformatics for these CoVs have enabled the creation of" exact="screening" post="models, which have been used to develop small molecule"/>
 <result pre="inhibit the replication of hCoV-229E, indicating its potential as a" exact="treatment" post="for human CoV infection. Management of inflammation is important"/>
 <result pre="SARS to MERS, Thrusting Coronaviruses into the SpotlightViruses111201959 10KilianskiA.BakerS.C.Cell-based antiviral" exact="screening" post="against coronaviruses: developing virus-specific and broad-spectrum inhibitorsAntiviral Res101201410511224269477 11PaulesC.I.MarstonH.D.FauciA.S.Coronavirus"/>
 <result pre="MERS- and SARS-coronavirus replication in cell culture, but not SARS-coronavirus" exact="infection" post="in a mouse modelVirus Res228201771327840112 40MaS.BoernerJ.E.TiongyipC.NIM811, a cyclophilin inhibitor,"/>
</results>
